Debevoise Advises Allergan in Its Sale of Brazikumab to AstraZeneca and Zenpep to Nestle

27 January 2020

Debevoise & Plimpton LLP is advising Allergan plc (NYSE: AGN), a leading global pharmaceutical company, in its sale of brazikumab (IL-23 inhibitor) to AstraZeneca and Zenpep® (pancrelipase) to Nestle. For more information, please see the company’s press release.

Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Brazikumab is a monoclonal antibody that binds to the IL23 receptor and is in development for Crohn’s Disease and Ulcerative Colitis with a companion biomarker. ZENPEP® (pancrelipase) is a prescription medication for people who cannot digest food normally because their pancreas does not make enough enzymes.

The Debevoise team is led by M&A partner Andrew Bab and includes M&A partners Jennifer Chu, Sue Meng and Thomas Schürrle, counsel Molly Stockley and associates William Barlow, Lauren Beasley, David Becker, Zhiyan Cao, Benjamin Collins-Wood, Michelle Guo, James Harrington, Gabriel Pollack and Friedrich Popp, tax partner Gary Friedman and associate Samuel Krawiecz, benefits partner Jonathan Lewis, intellectual property partner Henry Lebowitz and associate Jose Lamarque and FDA regulatory partner Paul Rubin and associate Melissa Runsten.